Moving the Drug Pipeline Forward with Mechanistic Modeling
In this GENcast, sponsored by Applied BioMath, we sat down with an expert in mechanistic modeling to discuss the specific of this approach and how companies are employing the technology successfully.
GENcast: The Quiet Voice of Immunotherapy That’s Starting to Be Heard
In this GENcast, our guest will tell us more about HTS using 3D cell models and why they are so crucial for current drug discovery projects. Moreover, he will provide scientific insight into the 3D cell panel screening service—called OncoSignature™—which uses a library of 200 cell lines grown in 3D spheroids to provide a better understanding of candidate cancer therapeutics.
Materials Sourcing: Precautions and Improvements for Cell and Gene Therapies
In this GENcast, sponsored by Applied BioMath, we sat down with an expert in mechanistic modeling to discuss the specific of this approach and how companies are employing the technology successfully
Helping Biosimilars Emerge into Global Markets Takes a Practiced Hand
Currently, almost 60 percent of drugs in development are being created by emerging biotech companies focused on therapies for niche diseases with small patient...
Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development
In this GENcast, sponsored by Applied BioMath, we sat down with an expert in mechanistic modeling to discuss the specific of this approach and how companies are employing the technology successfully.
Virtual Collaborations Push Pharma Forward During Pandemic
With regions of the world cycling through societal re-openings and shutdowns due to the ongoing coronavirus pandemic, pharma and life science companies are tasked...
Resins Address Downstream Purification Concerns
In this GENcast, sponsored by Applied BioMath, we sat down with an expert in mechanistic modeling to discuss the specific of this approach and how companies are employing the technology successfully.
Exploring Novel Vaccine Characterization Methodologies
In this GEN webinar, we will discuss some typical workflows used to characterize the properties of vaccines, looking at properties such as particle size, surface charge, aggregation, and protein secondary structure.
The Therapeutic Antibody Screening Revolution in the Post Genomics Era
In this GEN webinar, sponsored by Carterra, we will demonstrate how modern day high-throughput surface plasmon resonance (HT-SPR™) has facilitated a paradigm shift in antibody screening, enabling higher information content assays to be conducted earlier in the research pipeline to streamline lead selection. This essentially combines screening and detailed characterization in the same step, condensing months of work into days.
